The Food and Drug Administration has issued an emergency authorization for convalescent plasma as a ‘promising’ coronavirus treatment in the US, concluding that the known and potential benefits of the product “outweigh the risks.”
The treatment, which is already widely available and has been given to tens of thousands of patients, involves treating sufferers with a liquid made from the blood of people who have recovered from the illness.
The EUA authorizes the distribution of #COVID19 convalescent plasma in the U.S. and its administration by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in hospitalized COVID-19 patients.
Many medical experts have said the treatment could be helpful to treat the Covid-19 virus, but some say it may not be the breakthrough needed to deal with the pandemic.
On Saturday, Trump accused FDA Commissioner Stephen Hahn and the "deep state" of delaying approval on Covid-19 treatments until after the election. He had earlier said the agency was making a “political decision” in delaying it to hurt his election chances.
Former FDA commissioner Scott Gottlieb said on CBS News' Face The Nation on Sunday that there were "perceived delays" in authorizing it.
Gottlieb said that while the plasma treatment could be beneficial, "there's reasons people have questions about it" and that the trial based on 70,000 patients "wasn't a very rigorously done trial."
He rejected the idea that the FDA was making political decisions, saying it is a “foundational truth that what guides that agency is science."
0 Comments